Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC ...Middle East

HONG KONG, Feb. 12, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION-30/AK104-309) for its independently developed...

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC )

Also on site :

• Beloved brand ends controversial 50 cent fee on popular breakfast staple as it gets ahead of Waffle House
• Wimbledon: Naomi Osaka loses to Anastasia Pavlyuchenkova in the 3rd round
• Should You Expect USPS Mail Delivery on July 4th?